HER2 in Mucinous Ovarian Carcinoma: An Educational Overview of a Histotype-Specific Predictive Biomarker

Introduction and context

Ovarian carcinoma is not a single disease but a family of histotypes with distinct biology, molecular drivers, and clinical behavior. Mucinous carcinoma is one of the less common histotypes, and it differs meaningfully from the more familiar high-grade serous carcinoma [1]. Within this mucinous subset, a proportion of tumors show alterations in the HER2 (ERBB2) gene or its protein product—an observation with potential predictive relevance. This article explains, for a mixed audience of pathologists, trainees, clinicians, and informed patients, what HER2 testing measures in mucinous ovarian carcinoma, how it is performed and scored, and what each result state does and does not determine.

What the test measures (brief biology)

HER2 (human epidermal growth factor receptor 2) is a cell-surface receptor tyrosine kinase encoded by the ERBB2 gene. When the gene is amplified (present in extra copies) or the protein is overexpressed (present at abnormally high density on the cell membrane), it can drive proliferative signaling. In a subset of ovarian mucinous carcinomas, HER2 overexpression and gene amplification are present, and the published evidence indicates this subset can be a target for HER2-directed antibody therapy such as trastuzumab [2]. Importantly, this is a histotype-specific phenomenon: the rationale for HER2 testing here rests on evidence generated specifically in mucinous ovarian tumors [1,2], not on extrapolation from unrelated ovarian histotypes.

How it is tested

Specimen and preanalytics. Testing is performed on formalin-fixed, paraffin-embedded (FFPE) tissue—the standard archival format for surgical and biopsy specimens. As with any protein- and nucleic-acid-based assay on FFPE material, results depend on adequate fixation and tissue preservation; poorly fixed, over-fixed, or degraded tissue can compromise both immunohistochemistry (IHC) and in situ hybridization (ISH) interpretation.

Assays. Two complementary methods are used:

• Immunohistochemistry (IHC) detects HER2 protein at the cell membrane, providing a semiquantitative readout of overexpression.
• In situ hybridization (ISH) detects ERBB2 gene copy number, identifying amplification directly at the DNA level.

In practice these are often used in tandem: IHC serves as an accessible first-line assessment of protein expression, and ISH resolves cases where protein-level results are equivocal or where gene-level confirmation is desired.

Scoring. The interpretive goal is to identify amplification and/or overexpression in the mucinous carcinoma subset [2]. Scoring integrates the membranous staining pattern and intensity on IHC with gene copy-number status on ISH to arrive at a categorical call. Because the assays measure different molecular layers (protein versus gene), correlating the two is central to a confident result.

What each result state means

HER2 positive. The tumor demonstrates HER2 protein overexpression and/or ERBB2 gene amplification. In the context of mucinous ovarian carcinoma, this identifies the biologically defined subset in which HER2 is an active driver and a potential therapeutic target [2].

HER2 negative. The tumor does not show HER2 overexpression or amplification at the thresholds applied. This is the expected result in the majority of mucinous carcinomas, since HER2 alteration characterizes only a subset [2].

A result reflects the tissue analyzed and the assay thresholds used; it is a molecular characterization of the tumor, not a prognosis or a treatment prescription.

What it determines for treatment eligibility

HER2 in mucinous ovarian carcinoma is a predictive biomarker: its purpose is to inform whether a tumor falls into a category that may be eligible for HER2-directed therapeutic approaches. The published evidence suggests that HER2-positive mucinous ovarian carcinomas can be targeted with anti-HER2 antibody therapy such as trastuzumab [2]. Framed appropriately for education: a HER2-positive result informs eligibility for the HER2-directed therapy class, and in ovarian mucinous carcinoma this remains an emerging and largely trial-associated context rather than an established standard-of-care pathway.

This distinction matters. Determining eligibility for a drug class is a laboratory-and-clinical characterization step. It is not, and should not be read as, individualized treatment advice. Whether any particular therapy is appropriate for a given person is a clinical decision made by the treating team, weighing the full clinical picture. The role of the diagnostic is to establish the molecular fact—HER2 positive or negative—that feeds into that conversation.

Caveats and what is evolving

Several points warrant epistemic caution:

• Emerging evidence base. The supporting literature establishes that a HER2-positive subset exists and can be targeted [2], but the use of HER2-directed therapy in mucinous ovarian carcinoma remains an emerging and trial-oriented area rather than a settled treatment paradigm. Readers should regard the therapeutic linkage as promising but not definitively established.

• Rarity and study size. Because mucinous ovarian carcinoma is uncommon, histotype-specific datasets are inherently limited, and confidence intervals around any estimate are correspondingly wide.

• Contested cutoffs and "HER2-low." Across HER2 testing more broadly, the definitions and thresholds that separate positive, negative, and intermediate categories are an area of active debate. The concept of "HER2-low"—tumors with low-level protein expression that do not meet classic positivity criteria—is evolving and its relevance in the ovarian mucinous setting is not established by the records available here. Any scoring scheme should be applied and interpreted with this fluidity in mind.

• Histotype accuracy is prerequisite. Because this biomarker's rationale is histotype-specific, correct classification of the tumor as mucinous carcinoma—and exclusion of metastatic mucinous tumors of non-ovarian origin, a well-recognized diagnostic pitfall—underpins the validity of the entire HER2 workup [1].

Summary

HER2 testing in mucinous ovarian carcinoma, performed by IHC and ISH on FFPE tissue, identifies a biologically distinct subset defined by protein overexpression and/or gene amplification [1,2]. A positive result informs eligibility for the HER2-directed therapy class in an emerging, trial-associated context; a negative result reflects the more common state. Accurate histotype assignment, careful preanalytics, integrated IHC–ISH scoring, and awareness of evolving thresholds are all essential to a reliable interpretation.

References

1. WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed. IARC, Lyon; 2020. ISBN 978-92-832-4504-9.
2. McAlpine JN, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer; 2009. PMCID: PMC2803495.